Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CETP | P11597 | 18/20 | 0.53 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.51 |
| ▸ | CASR | P41180 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL532052 | 0.88 | CETP (0.53) | CETPNR1I2CASR | |
| SCHEMBL12521127 | 0.85 | CETP (0.48) | CETPNR1I2CASR | |
| SCHEMBL153790 | 0.84 | AKR1C3 (0.47) | CETPNR1I2 | |
| SCHEMBL5165035 | 0.83 | CETP (0.54) | CETPNR1I2CASR | |
| SCHEMBL131914 | 0.82 | ERN1 (0.41) | CETPNR1I2 | |
| SCHEMBL23846705 | 0.82 | CETP (0.53) | CETPNR1I2CASR | |
| SCHEMBL29786780 | 0.82 | CETP (0.53) | CETPNR1I2CASR | |
| SCHEMBL4011735 | 0.82 | CETP (0.57) | CETPNR1I2 | |
| SCHEMBL5165026 | 0.81 | CETP (0.53) | CETPNR1I2CASR | |
| SCHEMBL531531 | 0.81 | CETP (0.54) | CETPNR1I2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160075724-A1 | CETP Inhibitors | MERCK SHARP & DOHME (US) | 2016-03-17 | — | — | US | disclosed |
| US-20140221383-A1 | CETP INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2014-08-07 | — | — | US | disclosed |
| US-8735435-B2 | CETP inhibitors | MERCK SHARP & DOHME CORP. (US) | 2014-05-27 | — | — | US | disclosed |
| US-8440702-B2 | 1,3-oxazolidin -2-one derivatives useful as CETP inhibitors | MERCK SHARP & DOHME CORP. (US) | 2013-05-14 | — | — | US | disclosed |
| EP-2029560-B1 | 1,3-OXAZOLIDIN-2-ONE DERIVATIVES USEEFUL AS CETP INHIBITORS | MERCK SHARP & DOHME (US) | 2013-04-24 | — | — | EP | disclosed |
| EP-1765793-B1 | ANACETRAPIB AND OTHER CETP INHIBITPRS | MERCK SHARP & DOHME (US) | 2012-09-26 | — | — | EP | disclosed |
| EP-1979331-B1 | TRISUBSTITUTED AMINE COMPOUNDS AS INHIBITORS OF -CHOLESTERYL ESTER TRANSFER PROTEIN CETP | MITSUBISHI TANABE PHARMA CORP (JP) | 2012-03-07 | — | — | EP | disclosed |
| EP-2415759-A1 | CETP inhibitors | Merck Sharp & Dohme Corporation (US) | 2012-02-08 | — | — | EP | disclosed |
| US-8076364-B2 | Trisubstituted amine compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2011-12-13 | — | — | US | disclosed |
| US-20110178059-A1 | 1,3-OXAZOLIDIN -2-ONE DERIVATIVES USEFUL AS CETP INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2011-07-21 | — | — | US | disclosed |
| EP-1979331-A1 | TRISUBSTITUTED AMINE COMPOUNDS AS INHIBITORS OF -CHOLESTERYL ESTER TRANSFER PROTEIN CETP | Mitsubishi Tanabe Pharma Corporation (JP) | 2008-10-15 | — | — | EP | disclosed |
| US-20080119476-A1 | Cetp Inhibitors | ALI AMJAD | 2008-05-22 | — | — | US | disclosed |
| EP-1817297-A1 | DIBENZYL AMINE COMPOUNDS AND DERIVATIVES | Pfizer Products Inc. (US) | 2007-08-15 | — | — | EP | disclosed |
| WO-2007088996-A1 | TRISUBSTITUTED AMINE COMPOUNDS AS INHIBITORS OF -CHOLESTERYL ESTER TRANSFER PROTEIN CETP | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2007-08-09 | — | — | WO | disclosed |
| WO-2007079186-A2 | 1, 3-OXAZOLIDIN-2-ONE DERIVATIVES USEFUL AS CETP INHIBITORS | MERCK & CO., INC. (US) | 2007-07-12 | — | — | WO | disclosed |
| EP-1765793-A1 | CETP INHIBITORS | Merck and Co., Inc. (US) | 2007-03-28 | — | — | EP | disclosed |
| WO-2006056854-A1 | DIBENZYL AMINE COMPOUNDS AND DERIVATIVES | PFIZER PRODUCTS INC. (US) | 2006-06-01 | — | — | WO | disclosed |
| US-20060040999-A1 | CETP inhibitors | MERCK SHARP & DOHME LLC | 2006-02-23 | — | — | US | disclosed |
| WO-2006014357-A1 | CETP INHIBITORS | MERCK & CO., INC. (US) | 2006-02-09 | — | — | WO | disclosed |
| WO-2006014413-A1 | CETP INHIBITORS | MERCK & CO., INC. (US) | 2006-02-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140221383-A1 | CETP INHIBITORS | CETP, APOB, MTTP | CETP 1/4885NR1I2 67/4885CASR 4268/4885 |
| US-20060040999-A1 | CETP inhibitors | CETP, APOB, MTTP | CETP 1/4885NR1I2 67/4885CASR 4268/4885 |
| US-20080119476-A1 | Cetp Inhibitors | CETP, APOB, MTTP | CETP 1/4885NR1I2 67/4885CASR 4268/4885 |
| US-20110178059-A1 | 1,3-OXAZOLIDIN -2-ONE DERIVATIVES USEFUL AS CETP INHIBITORS | CETP, MTTP, APOB | CETP 1/4885NR1I2 111/4885CASR 4853/4885 |
| US-20160075724-A1 | CETP Inhibitors | CETP, APOB, MTTP | CETP 1/4885NR1I2 67/4885CASR 4268/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.